Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
- Anna Li
- Wei-Neng Feng
- Juan Li
- Bing-Fei Xu
- Jun Zhao
- Yun Jia
- Ke-Jing Tang
- Yong-Sheng Li
- Cheng-Zhi Zhou
- Yun Fan
- Chong-Rui Xu
- Yue-Li Sun
- Hua-Jun Chen
- Hong-Hong Yan
- Zong-Kun Shi
- Jin-Ji Yang
2026-01-13